Biomarin Pharmaceutical price to free cash flow BMRN
Market value divided by free cash flow over the last twelve months, since 2021.
- Today, Nov 2, 2026
- 15.1×
- 6-year median
- 78.6×
- Against its 6-year history
- 18th
- percentile: 0 is its lowest day, 100 its highest
- 6-year range
- 11.9× to 499×
- Peer median
- 51.1×
Biomarin Pharmaceutical's price to free cash flow is 15.1× as of Nov 2, 2026.
That is below its 6-year median of 78.6×, lower than on 82% of days in the last 6 years.
Over that time it ranged from 11.9× in Nov 2025 to 499× in Dec 2023.
The median for 10 large drugmakers of a similar size is 51.1×.
Price to free cash flow over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 15.1× | 12.6× | 17.7× |
| 2025 | 13.8× | 11.9× | 40.7× |
| 2024 | 39.9× | 37.8× | 495× |
| 2023 | 499× | 286× | 499× |
| 2022 | 290× | 66.9× | 353× |
| 2021 | 89.1× | 78.0× | 136× |
Against its peers
Companies in Drug Manufacturers - General nearest Biomarin Pharmaceutical's size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| BMRNBiomarin Pharmaceutical | 15.1× |
| TGTXTG Therapeutics | n/m |
| PTGXProtagonist Therapeutics | 69.1× |
| JAZZJazz Pharmaceuticals | 8.7× |
| CORTCorcept Therapeutics | 81.3× |
| ALKSAlkermes plc. | 34.0× |
| KNSAKiniksa Pharmaceuticals International | 38.7× |
| AMRXAmneal Pharmaceuticals | 51.1× |
| LGNDLigand Pharmaceuticals | 46.6× |
| INDVIndivior Pharmaceuticals | 138× |
| ARQTArcutis Biotherapeutics | 100× |
| Peer median | 51.1× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on Biomarin Pharmaceutical
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.